What is the share price of SeQuent Scientific Ltd (SEQUENT) today?
The share price of SEQUENT as on 23rd June 2025 is ₹184.41. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on SeQuent Scientific Ltd (SEQUENT) share?
The past returns of SeQuent Scientific Ltd (SEQUENT) share are- Past 1 week: -4.34%
- Past 1 month: 4.87%
- Past 3 months: 27.44%
- Past 6 months: 5.16%
- Past 1 year: 56.04%
- Past 3 years: 91.10%
- Past 5 years: 98.18%
What are the peers or stocks similar to SeQuent Scientific Ltd (SEQUENT)?
The peers or stocks similar to SeQuent Scientific Ltd (SEQUENT) include:What is the market cap of SeQuent Scientific Ltd (SEQUENT) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of SeQuent Scientific Ltd (SEQUENT) is ₹4608.27 Cr as of 23rd June 2025.What is the 52 week high and low of SeQuent Scientific Ltd (SEQUENT) share?
The 52-week high of SeQuent Scientific Ltd (SEQUENT) is ₹240.70 and the 52-week low is ₹116.40.What is the PE and PB ratio of SeQuent Scientific Ltd (SEQUENT) stock?
The P/E (price-to-earnings) ratio of SeQuent Scientific Ltd (SEQUENT) is 210.62. The P/B (price-to-book) ratio is 6.46.Which sector does SeQuent Scientific Ltd (SEQUENT) belong to?
SeQuent Scientific Ltd (SEQUENT) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy SeQuent Scientific Ltd (SEQUENT) shares?
You can directly buy SeQuent Scientific Ltd (SEQUENT) shares on Tickertape. Simply sign up, connect your demat account and place your order.
SeQuent Scientific Ltd
SEQUENT Share Price
SEQUENT Stock Scorecard
Performance
AvgPrice return has been average, nothing exciting
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
AvgAverage profitability - not good, not bad
Entry point
AvgThe stock is not in the overbought zone
Red flags
AvgThe stock has a moderate number of red flags
How to use scorecard? Learn more
SEQUENT Performance & Key Metrics
SEQUENT Performance & Key Metrics
No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
---|---|---|
213.68 | 6.56 | — |
Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
---|---|---|
35.51 | 6.52 | 0.85% |
SEQUENT Analyst Ratings & Forecast
Price Upside
Earnings Growth
Rev. Growth
SEQUENT Company Profile
SeQuent Scientific Limited is a holding company that operates in pharmaceutical sector.
SEQUENT Sentiment Analysis
SEQUENT Sentiment Analysis
SEQUENT Stock Summary · May 2025
In Q4 FY25, the company achieved a remarkable turnaround, reporting a profit after tax of INR 322 million, a 208.9% increase from the previous year’s loss, driven by an 11.2% revenue growth to INR 4,017 million. The formulations business thrived with nearly 20% growth, while the API segment showed signs of recovery, bolstered by strategic initiatives and a focus on operational efficiency. Despite challenges with cash flow conversion due to high inventory levels, management remains optimistic about future growth, particularly with the upcoming merger with Viyash Life Sciences, which is expected to enhance R&D capabilities and operational performance. The company is also expanding its companion animal health segment and pursuing opportunities in the CDMO space, positioning itself for sustained growth and improved margins.
SEQUENT Stock Growth Drivers
SEQUENT Stock Growth Drivers
7Strong Financial Performance
SeQuent Scientific Limited reported robust financial results for Q4 FY '25, achieving revenues of INR
Improved Margins and Profitability
The company achieved a significant turnaround in profit after tax, moving from a loss in
SEQUENT Stock Challenges
SEQUENT Stock Challenges
5Revenue Decline
The company has experienced a 3% decline in revenue quarter-on-quarter, attributed to inventory buildup in
Limited Product Offering in Companion Animal Health
Currently, the companion animal health segment constitutes less than 10% of the company's product offerings.
SEQUENT Forecast
SEQUENT Forecasts
SEQUENT
SEQUENT
Income
Balance Sheet
Cash Flow
SEQUENT Income Statement
SEQUENT Income Statement
Financial Year | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Total Revenue | 694.65 | 1,292.62 | 1,047.98 | 1,189.33 | 1,369.98 | 1,423.67 | 1,427.30 | 1,395.45 | 1,566.06 | 1,566.06 | ||||||||||
Raw Materials | 366.89 | 486.44 | 570.52 | 600.59 | 733.68 | 842.41 | 814.87 | 789.20 | 1,394.55 | 1,394.55 | ||||||||||
Power & Fuel Cost | 12.77 | 14.66 | 23.06 | 24.73 | 28.75 | 33.86 | 42.45 | 35.46 | ||||||||||||
Employee Cost | 106.22 | 113.83 | 145.95 | 165.06 | 187.22 | 231.37 | 258.39 | 250.57 | ||||||||||||
Selling & Administrative Expenses | 74.68 | 94.72 | 90.93 | 108.27 | 115.85 | 132.65 | 139.02 | 138.35 | ||||||||||||
Operating & Other expenses | 82.59 | 64.28 | 83.92 | 110.27 | 92.86 | 63.12 | 219.02 | 126.88 | ||||||||||||
EBITDA | 51.50 | 518.69 | 133.60 | 180.41 | 211.62 | 120.26 | -46.45 | 54.99 | 171.51 | 171.51 | ||||||||||
Depreciation/Amortization | 40.07 | 41.34 | 41.92 | 50.62 | 50.60 | 51.54 | 55.69 | 61.54 | 66.45 | 66.45 | ||||||||||
PBIT | 11.43 | 477.35 | 91.68 | 129.79 | 161.02 | 68.72 | -102.14 | -6.55 | 105.06 | 105.06 | ||||||||||
Interest & Other Items | 28.34 | 33.07 | 32.80 | 35.71 | 24.38 | 15.77 | 35.52 | 48.09 | 60.75 | 60.75 | ||||||||||
PBT | -16.91 | 444.28 | 58.88 | 94.08 | 136.64 | 52.95 | -137.66 | -54.64 | 44.31 | 44.31 | ||||||||||
Taxes & Other Items | -3.08 | 22.72 | 10.22 | 24.17 | 41.19 | 11.98 | -16.50 | -18.77 | 22.43 | 22.43 | ||||||||||
Net Income | -13.83 | 421.56 | 48.66 | 69.91 | 95.45 | 40.97 | -121.16 | -35.87 | 21.88 | 21.88 | ||||||||||
EPS | -0.53 | 15.98 | 1.91 | 2.82 | 3.84 | 1.65 | -4.87 | -1.44 | 0.88 | 0.88 | ||||||||||
DPS | 0.00 | 0.18 | 0.20 | 0.00 | 0.50 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||||||
Payout ratio | 0.00 | 0.01 | 0.10 | 0.00 | 0.13 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SEQUENT Company Updates
Investor Presentation
SEQUENT Stock Peers
SEQUENT Past Performance & Peer Comparison
SEQUENT Past Performance & Peer Comparison
Health CarePharmaceuticals
Valuation
Technical
Forecast
Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
---|---|---|---|
SeQuent Scientific Ltd | 213.68 | 6.56 | — |
Sun Pharmaceutical Industries Ltd | 36.56 | 5.95 | 0.96% |
Cipla Ltd | 22.97 | 4.52 | 1.07% |
Dr Reddy's Laboratories Ltd | 19.50 | 3.90 | 0.61% |
SEQUENT Stock Price Comparison
Compare SEQUENT with any stock or ETFSEQUENT Holdings
SEQUENT Shareholdings
SEQUENT Promoter Holdings Trend
SEQUENT Promoter Holdings Trend
In last 6 months, promoter holding in the company has almost stayed constant
Pledged promoter holdings is insignificant
SEQUENT Institutional Holdings Trend
SEQUENT Institutional Holdings Trend
In last 3 months, retail holding in the company has almost stayed constant
In last 3 months, foreign institutional holding of the company has almost stayed constant
SEQUENT Shareholding Pattern
SEQUENT Shareholding Pattern
SEQUENT Shareholding History
SEQUENT Shareholding History
Mutual Funds Invested in SEQUENT
Mutual Funds Invested in SEQUENT
No mutual funds holding trends are available
Top 5 Mutual Funds holding SeQuent Scientific Ltd
Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
---|---|---|---|---|
The rupee value of the stock held by the fund divided by the stock’s market cap 8.9064% | Percentage of the fund’s portfolio invested in the stock 1.53% | Change in the portfolio weight of the stock over the last 3 months 0.07% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 15/112 (+2) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.5847% | Percentage of the fund’s portfolio invested in the stock 6.80% | Change in the portfolio weight of the stock over the last 3 months 1.04% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 11/27 (-1) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.3448% | Percentage of the fund’s portfolio invested in the stock 1.57% | Change in the portfolio weight of the stock over the last 3 months -0.04% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 27/45 (-2) |
Compare 3-month MF holding change on Screener
smallcases containing SEQUENT stock
smallcases containing SEQUENT stock
Looks like this stock is not in any smallcase yet.
SEQUENT Events
SEQUENT Events
SEQUENT Dividend Trend
No dividend trend available
Dividends
Corp. Actions
Announcements
Legal Orders
SEQUENT Dividend Trend
No dividend trend available
SEQUENT Upcoming Dividends
SEQUENT Upcoming Dividends
No upcoming dividends are available
SEQUENT Past Dividends
SEQUENT Past Dividends
Cash Dividend
Ex DateEx DateSep 8, 2021
Dividend/Share
₹0.50
Ex DateEx Date
Sep 8, 2021
Cash Dividend
Ex DateEx DateAug 21, 2019
Dividend/Share
₹0.20
Ex DateEx Date
Aug 21, 2019
Cash Dividend
Ex DateEx DateNov 20, 2017
Dividend/Share
₹0.20
Ex DateEx Date
Nov 20, 2017
Cash Dividend
Ex DateEx DateSep 16, 2011
Dividend/Share
₹1.50
Ex DateEx Date
Sep 16, 2011
Cash Dividend
Ex DateEx DateSep 23, 2010
Dividend/Share
₹2.00
Ex DateEx Date
Sep 23, 2010
SEQUENT Stock News & Opinions
SEQUENT Stock News & Opinions
Sequent Scientific has approved the issue and allotment of 3,000 Equity Shares of Rs. 2/- each fully paid to one Employee at an exercise price of Rs. 86/- per equity share on exercise of the options granted to him under SeQuent ESOP 2020.Powered by Capital Market - Live
Net profit of Sequent Scientific reported to Rs 9.32 crore in the quarter ended March 2025 as against net loss of Rs 0.92 crore during the previous quarter ended March 2024. Sales rose 11.21% to Rs 401.70 crore in the quarter ended March 2025 as against Rs 361.20 crore during the previous quarter ended March 2024. For the full year,net profit reported to Rs 21.88 crore in the year ended March 2025 as against net loss of Rs 35.88 crore during the previous year ended March 2024. Sales rose 13.26% to Rs 1551.37 crore in the year ended March 2025 as against Rs 1369.73 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales401.70361.20 11 1551.371369.73 13 OPM %11.518.93 -10.434.48 - PBDT32.7723.83 38 115.7324.28 377 PBT16.657.35 127 49.28-37.26 LP NP9.32-0.92 LP 21.88-35.88 LP Powered by Capital Market - Live
Sequent Scientific will hold a meeting of the Board of Directors of the Company on 20 May 2025.Powered by Capital Market - Live
Net profit of Sequent Scientific declined 58.40% to Rs 3.44 crore in the quarter ended December 2024 as against Rs 8.27 crore during the previous quarter ended December 2023. Sales rose 18.66% to Rs 390.81 crore in the quarter ended December 2024 as against Rs 329.36 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales390.81329.36 19 OPM %8.836.76 - PBDT25.3914.19 79 PBT8.41-1.27 LP NP3.448.27 -58 Powered by Capital Market - Live
Sequent Scientific will hold a meeting of the Board of Directors of the Company on 11 February 2025.Powered by Capital Market - Live
Sequent Scientific announced that the Competition Commission of India vide its letter dated 21 January 2025 has approved the composite Scheme of amalgamation amongst Sequent Scientific, Symed Labs, Vandana Life Sciences, Appcure Labs, Vindhya Pharma (India), S.V. Labs, Vindhya Organics, Viyash Life Sciences, Geninn Life Sciences and Sequent Research and their respective shareholders and the creditors. Powered by Capital Market - Live
Sequent Scientific has allotted 5,40,000 equity shares under ESOP on 23 November 2024. With this allotment, the paid up equity share capital has increased to Rs. Rs. 50,06,03,990/-consisting of 25,03,01,995 equity shares of Rs. 2/- each.Powered by Capital Market - Live
Sequent Scientific has completed the acquisition of 3.90% stake from Ms. Katarina Agren in N-VET AB through Alivira Animal Health, Ireland, Wholly Owned Subsidiary of the Company. The company also completed the acquisition of 3.75% stake from Renzo Rimondi and 1.25% from Ramon Vila Vina, collectively 5%, in Alivira Italia SRL, through Alivira Animal Health, Ireland, Wholly Owned Subsidiary of the Company. Consequent to the above acquisitions, N-VET AB and Alivira Italia SRL have become Wholly Owned Subsidiaries of the Company.Powered by Capital Market - Live
Sequent Scientific will hold a meeting of the Board of Directors of the Company on 13 November 2024Powered by Capital Market - Live
Sequent Scientific has approved the issue and allotment of 120,000 Equity Shares of Rs. 2/- each fully paid to two Employees at an exercise price of Rs. 86/- per equity share on exercise of the options granted to them under SeQuent ESOP 2020. Powered by Capital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of 5.89%, vs industry avg of 9.02%
Over the last 5 years, market share decreased from 0.48% to 0.37%